---
document_datetime: 2025-12-02 06:18:23
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/inomax.html
document_name: inomax.html
version: success
processing_time: 0.1312612
conversion_datetime: 2025-12-24 21:44:40.525378
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# INOmax

[RSS](/en/individual-human-medicine.xml/66767)

##### Authorised

This medicine is authorised for use in the European Union

nitric oxide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on INOmax](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for INOmax. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for INOmax.

Expand section

Collapse section

## What is INOmax?

INOmax is a gas for inhalation that contains the active substance nitric oxide diluted in nitrogen gas at 400 or 800 parts per million (ppm).

## What is INOmax used for?

INOmax is used in combination with artificial ventilation and other medicines to help improve blood oxygen levels in the following groups of patients:

- newborn babies (born after 34 weeks of gestation) with breathing problems associated with pulmonary hypertension (high blood pressure in the lungs). INOmax is used in these babies to improve oxygen supply levels and to reduce the need for extracorporeal membrane oxygenation (ECMO, a technique to oxygenate the blood outside the body using a device similar to a heart-lung machine);
- patients of all ages who are undergoing or have undergone heart surgery and develop pulmonary hypertension. In these patients, INOmax is used to help improve heart function and reduce blood pressure in the lungs.

The medicine can only be obtained with a prescription.

## How is INOmax used?

INOmax treatment should be supervised by a doctor who has experience in intensive care or neonatal intensive care if the patient is a newborn baby. INOmax should only be used in units where staff have been trained in the use of a nitric-oxide delivery system.

INOmax is used in patients who are undergoing artificial ventilation, once the ventilation is optimised. INOmax is given after being diluted in an oxygen / air mixture supplied to the patient through the ventilator.

The maximum starting dose of INOmax is 20 ppm for children up to 18 years of age, and 40 ppm for adults. This should then be reduced to 5 ppm, provided the blood in the arteries contains enough oxygen. In newborn babies with breathing problems, treatment can be continued at this dose until there is improvement in oxygen levels, for a maximum of four days. In children and adults undergoing heart surgery, treatment usually lasts for 24 to 48 hours. Treatment should not be stopped abruptly. For more information, see the summary of product characteristics.

## How does INOmax work?

The active substance in INOmax, nitric oxide, is a naturally occurring chemical in the body, which causes the muscles in the lining of the blood vessels to relax. When inhaled, it causes the vessels in the lungs to dilate (widen): this allows blood to flow more easily in the lungs to supply oxygen to the rest of the body and remove carbon dioxide, reducing pulmonary hypertension. It also helps to decrease inflammation in the lungs.

## How has INOmax been studied?

Because nitric oxide is a well known chemical, the company used data from the published literature to support INOmax's use in newborn babies with pulmonary hypertension, and in adults and children undergoing heart surgery.

INOmax has also been studied in 421 neonates from 34 weeks gestation with pulmonary hypertension in two main studies. In the first study, 235 neonates with respiratory failure received either INOmax or placebo (a dummy treatment). The main measure of effectiveness was the proportion of neonates who died or needed ECMO over the first 120 days in hospital. In the second study, 186 neonates with respiratory failure received either INOmax or placebo. The main measure of effectiveness was the proportion of neonates who needed ECMO.

## What benefit has INOmax shown during the studies?

In the two main studies in newborn babies with breathing problems, INOmax was more effective than placebo at reducing the need of ECMO. In the first main study, 52 (46%) of the 114 neonates receiving INOmax died or needed ECMO, compared with 77 (64%) of the 121 receiving placebo. This was mainly due to a reduction in the need for ECMO, rather than a reduction in death rates. In the second main study, 30 (31%) of the neonates receiving INOmax needed ECMO, compared with 51 (57%) of the 89 receiving placebo.

In the published literature, INOmax treatment was shown to reduce the blood pressure in the lungs and improve heart function when used during or after heart surgery.

## What is the risk associated with INOmax?

The most common side effect with INOmax (seen in more than 1 patient in 10) are thrombocytopenia (low blood platelet counts), hypokalaemia (low blood potassium levels), hypotension (low blood pressure), atelectasis (collapse of the whole, or part of a, lung), and hyperbilirubinaemia (high blood levels of bilirubin). For the full list of all side effects reported with INOmax, see the package leaflet.

INOmax should not be used in babies who may be hypersensitive (allergic) to nitric oxide or the other ingredient (nitrogen). It must not be used in babies who have right-to-left or significant left-to-right shunting of blood (abnormal circulation of blood in the heart).

## What measures are being taken to ensure the safe use of INOmax?

The company must put in place an educational programme to ensure that doctors who are going to use INOmax for the treatment of patients undergoing heart surgery are aware of the risks and the precautions necessary when using the medicine.

## Why has INOmax been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that INOmax's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about INOmax

The European Commission granted a marketing authorisation valid throughout the European Union for INOmax on 1 August 2001. The marketing-authorisation holder is Linde Healthcare AB. The marketing authorisation is valid for an unlimited period.

For more information about treatment with INOmax, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

INOmax : EPAR - Summary for the public

English (EN) (83.49 KB - PDF)

**First published:** 25/01/2008

**Last updated:** 28/02/2013

[View](/en/documents/overview/inomax-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-115)

български (BG) (132.58 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/bg/documents/overview/inomax-epar-summary-public_bg.pdf)

español (ES) (87.78 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/es/documents/overview/inomax-epar-summary-public_es.pdf)

čeština (CS) (133.71 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/cs/documents/overview/inomax-epar-summary-public_cs.pdf)

dansk (DA) (86.4 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/da/documents/overview/inomax-epar-summary-public_da.pdf)

Deutsch (DE) (88.05 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/de/documents/overview/inomax-epar-summary-public_de.pdf)

eesti keel (ET) (81.82 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/et/documents/overview/inomax-epar-summary-public_et.pdf)

ελληνικά (EL) (114.93 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/el/documents/overview/inomax-epar-summary-public_el.pdf)

français (FR) (107.2 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/fr/documents/overview/inomax-epar-summary-public_fr.pdf)

italiano (IT) (86.15 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/it/documents/overview/inomax-epar-summary-public_it.pdf)

latviešu valoda (LV) (104.95 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/lv/documents/overview/inomax-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (111.65 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/lt/documents/overview/inomax-epar-summary-public_lt.pdf)

magyar (HU) (108.85 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/hu/documents/overview/inomax-epar-summary-public_hu.pdf)

Malti (MT) (111.98 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/mt/documents/overview/inomax-epar-summary-public_mt.pdf)

Nederlands (NL) (84.6 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/nl/documents/overview/inomax-epar-summary-public_nl.pdf)

polski (PL) (109.69 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/pl/documents/overview/inomax-epar-summary-public_pl.pdf)

português (PT) (104.71 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/pt/documents/overview/inomax-epar-summary-public_pt.pdf)

română (RO) (109.25 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/ro/documents/overview/inomax-epar-summary-public_ro.pdf)

slovenčina (SK) (109.46 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/sk/documents/overview/inomax-epar-summary-public_sk.pdf)

slovenščina (SL) (128.39 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/sl/documents/overview/inomax-epar-summary-public_sl.pdf)

Suomi (FI) (76.46 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/fi/documents/overview/inomax-epar-summary-public_fi.pdf)

svenska (SV) (105.27 KB - PDF)

**First published:**

25/01/2008

**Last updated:**

28/02/2013

[View](/sv/documents/overview/inomax-epar-summary-public_sv.pdf)

## Product information

INOmax : EPAR - Product Information

English (EN) (671.25 KB - PDF)

**First published:** 23/11/2009

**Last updated:** 15/05/2025

[View](/en/documents/product-information/inomax-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-368)

български (BG) (2.14 MB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/bg/documents/product-information/inomax-epar-product-information_bg.pdf)

español (ES) (670.1 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/es/documents/product-information/inomax-epar-product-information_es.pdf)

čeština (CS) (686.57 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/cs/documents/product-information/inomax-epar-product-information_cs.pdf)

dansk (DA) (680.85 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/da/documents/product-information/inomax-epar-product-information_da.pdf)

Deutsch (DE) (708.65 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/de/documents/product-information/inomax-epar-product-information_de.pdf)

eesti keel (ET) (628.17 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/et/documents/product-information/inomax-epar-product-information_et.pdf)

ελληνικά (EL) (775.28 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/el/documents/product-information/inomax-epar-product-information_el.pdf)

français (FR) (699.7 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/fr/documents/product-information/inomax-epar-product-information_fr.pdf)

hrvatski (HR) (677.42 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/hr/documents/product-information/inomax-epar-product-information_hr.pdf)

íslenska (IS) (683.29 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/is/documents/product-information/inomax-epar-product-information_is.pdf)

italiano (IT) (684.57 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/it/documents/product-information/inomax-epar-product-information_it.pdf)

latviešu valoda (LV) (705.23 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/lv/documents/product-information/inomax-epar-product-information_lv.pdf)

lietuvių kalba (LT) (711.42 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/lt/documents/product-information/inomax-epar-product-information_lt.pdf)

magyar (HU) (703.32 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/hu/documents/product-information/inomax-epar-product-information_hu.pdf)

Malti (MT) (721.8 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/mt/documents/product-information/inomax-epar-product-information_mt.pdf)

Nederlands (NL) (694.18 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/nl/documents/product-information/inomax-epar-product-information_nl.pdf)

norsk (NO) (669.2 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/no/documents/product-information/inomax-epar-product-information_no.pdf)

polski (PL) (724.49 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/pl/documents/product-information/inomax-epar-product-information_pl.pdf)

português (PT) (700.25 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/pt/documents/product-information/inomax-epar-product-information_pt.pdf)

română (RO) (689.88 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/ro/documents/product-information/inomax-epar-product-information_ro.pdf)

slovenčina (SK) (670.49 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/sk/documents/product-information/inomax-epar-product-information_sk.pdf)

slovenščina (SL) (676.36 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/sl/documents/product-information/inomax-epar-product-information_sl.pdf)

Suomi (FI) (629.95 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/fi/documents/product-information/inomax-epar-product-information_fi.pdf)

svenska (SV) (676.04 KB - PDF)

**First published:**

23/11/2009

**Last updated:**

15/05/2025

[View](/sv/documents/product-information/inomax-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000269511 15/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

INOmax : EPAR - All Authorised presentations

English (EN) (19.32 KB - PDF)

**First published:** 15/08/2006

**Last updated:** 30/03/2011

[View](/en/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-391)

български (BG) (54.02 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/bg/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_bg.pdf)

español (ES) (19.39 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/es/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_es.pdf)

čeština (CS) (51 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/cs/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (19.31 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/da/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (20.1 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/de/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (20.56 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/et/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (52.42 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/el/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_el.pdf)

français (FR) (18.87 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/fr/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (24.86 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/hr/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (19.86 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/is/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_is.pdf)

italiano (IT) (18.44 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/it/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (50.96 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/lv/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (51.25 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/lt/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (36.45 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/hu/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (51.57 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/mt/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (18.36 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/nl/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (19.7 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/no/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_no.pdf)

polski (PL) (33.31 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/pl/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_pl.pdf)

português (PT) (19.92 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/pt/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_pt.pdf)

română (RO) (51.53 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/ro/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (52.01 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/sk/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (20.47 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/sl/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (19.07 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/fi/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (19.83 KB - PDF)

**First published:**

15/08/2006

**Last updated:**

30/03/2011

[View](/sv/documents/all-authorised-presentations/inomax-epar-all-authorised-presentations_sv.pdf)

INOmax : EPAR - Conditions imposed on member states for safe and effective use - Annex IV

English (EN) (18.13 KB - PDF)

**First published:** 30/03/2011

**Last updated:** 30/03/2011

[View](/en/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_en.pdf)

[Other languages (23)](#file-language-dropdown-657)

български (BG) (86.87 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/bg/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_bg.pdf)

español (ES) (18.42 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/es/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_es.pdf)

čeština (CS) (86.14 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/cs/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_cs.pdf)

dansk (DA) (19.05 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/da/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_da.pdf)

Deutsch (DE) (18.6 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/de/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_de.pdf)

eesti keel (ET) (18.91 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/et/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_et.pdf)

ελληνικά (EL) (82.31 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/el/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_el.pdf)

français (FR) (18.64 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/fr/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fr.pdf)

íslenska (IS) (18.66 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/is/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_is.pdf)

italiano (IT) (18.49 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/it/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_it.pdf)

latviešu valoda (LV) (79.35 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/lv/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lv.pdf)

lietuvių kalba (LT) (85.5 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/lt/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lt.pdf)

magyar (HU) (57.09 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/hu/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_hu.pdf)

Malti (MT) (88.83 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/mt/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_mt.pdf)

Nederlands (NL) (18.82 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/nl/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_nl.pdf)

norsk (NO) (18.6 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/no/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_no.pdf)

polski (PL) (88.41 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/pl/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pl.pdf)

português (PT) (14.44 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/pt/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pt.pdf)

română (RO) (85.49 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/ro/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_ro.pdf)

slovenčina (SK) (85.25 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/sk/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sk.pdf)

slovenščina (SL) (81.1 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/sl/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sl.pdf)

Suomi (FI) (18.57 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/fi/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fi.pdf)

svenska (SV) (18.61 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

30/03/2011

[View](/sv/documents/conditions-member-states/inomax-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sv.pdf)

## Product details

Name of medicine INOmax Active substance nitric oxide International non-proprietary name (INN) or common name nitric oxide Therapeutic area (MeSH)

- Hypertension, Pulmonary
- Respiratory Insufficiency

Anatomical therapeutic chemical (ATC) code R07AX

### Pharmacotherapeutic group

Other respiratory system products

### Therapeutic indication

INOmax, in conjunction with ventilatory support and other appropriate active substances, is indicated:

- for the treatment of newborn infants ?34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;
- as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.

## Authorisation details

EMA product number EMEA/H/C/000337 Marketing authorisation holder

Linde Healthcare AB

Rättarvägen 3

Marketing authorisation issued 01/08/2001 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

INOmax : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (218.2 KB - PDF)

**First published:** 27/03/2025

**Last updated:** 15/05/2025

[View](/en/documents/procedural-steps-after/inomax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

INOmax : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (1.37 MB - PDF)

**First published:** 23/11/2009

**Last updated:** 27/03/2025

[View](/en/documents/procedural-steps-after/inomax-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

INOmax-H-C-337-P46-18 : EPAR - Assessment Report

Adopted

English (EN) (217.6 KB - PDF)

**First published:** 28/02/2013

**Last updated:** 28/02/2013

[View](/en/documents/variation-report/inomax-h-c-337-p46-18-epar-assessment-report_en.pdf)

INOmax-H-C-337-P45-19: EPAR - Assessment Report

Adopted

Reference Number: EMEA/307669/2010

English (EN) (145.07 KB - PDF)

**First published:** 13/11/2012

**Last updated:** 13/11/2012

[View](/en/documents/variation-report/inomax-h-c-337-p45-19-epar-assessment-report_en.pdf)

INOmax-H-C-337-II-19 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/231748/2011

English (EN) (479.33 KB - PDF)

**First published:** 04/04/2011

**Last updated:** 04/04/2011

[View](/en/documents/variation-report/inomax-h-c-337-ii-19-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for INOmax

Adopted

Reference Number: EMA/CHMP/733047/2010

English (EN) (132.06 KB - PDF)

**First published:** 21/01/2011

**Last updated:** 21/01/2011

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-inomax_en.pdf)

## Initial marketing authorisation documents

INOmax : EPAR - Procedural steps taken before authorisation

English (EN) (1.37 MB - PDF)

**First published:** 15/08/2006

**Last updated:** 20/04/2023

[View](/en/documents/procedural-steps/inomax-epar-procedural-steps-taken-authorisation_en.pdf)

INOmax : EPAR - Scientific Discussion

English (EN) (298.23 KB - PDF)

**First published:** 15/08/2006

**Last updated:** 15/08/2006

[View](/en/documents/scientific-discussion/inomax-epar-scientific-discussion_en.pdf)

#### More information on INOmax

- [EMEA-000612-PIP01-09 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000612-pip01-09)
- [INOmax - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/inomax)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 15/05/2025

## Share this page

[Back to top](#main-content)